Reuters logo
BUZZ-India's Cadila Healthcare hits record high on US FDA approval
June 7, 2017 / 4:36 AM / 4 months ago

BUZZ-India's Cadila Healthcare hits record high on US FDA approval

** Cadila Healthcare shares rise as much as 9.9 pct to record high

** Zydus Cadila gets final approval from U.S. FDA for Mesalamine delayed-release tablets, 1.2 g

** Product to be manufactured at Moraiya manufacturing facility in India for US market

** Lialda (mesalamine) is indicated for treatment of mild to moderate ulcerative colitis, a chronic condition that causes inflammation in the digestive tract

** Over 3.4 mln shares change hands as of 0419 GMT, thrice the average 30-day trading volume

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below